Elafibranor activates PPAR-α, PPAR-γ and PPAR-δ in vitro, and has been developed for the treatment of PBC [175] and metabolic-associated steatotic liver disease (MASLD) [176]. This evidence concerns the gene PPARA and primary biliary cholangitis.